Anaplastic thyroid carcinoma: pathogenesis and emerging therapies
RC Smallridge, JA Copland - Clinical oncology, 2010 - Elsevier
Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally.
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
[HTML][HTML] Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
RC Smallridge, JA Copland - Clinical oncology (Royal College of …, 2010 - ncbi.nlm.nih.gov
Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally.
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
RC Smallridge, JA Copland - Clinical Oncology, 2010 - infona.pl
Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally.
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies
RC Smallridge, JA Copland - Clinical Oncology, 2010 - mayoclinic.pure.elsevier.com
Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally.
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.
RC Smallridge, JA Copland - Clinical Oncology (Royal College of …, 2010 - europepmc.org
Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally.
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Anaplastic thyroid carcinoma: pathogenesis and emerging therapies
RC Smallridge, JA Copland - Clinical oncology (Royal …, 2010 - pubmed.ncbi.nlm.nih.gov
Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally.
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
RC Smallridge, JA Copland - Clinical Oncology, 2010 - clinicaloncologyonline.net
Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally.
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies
RC Smallridge, JA Copland - Clinical Oncology, 2010 - mayoclinic.elsevierpure.com
Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally.
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
[引用][C] Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
RC Smallridge, JA Copland - Clinical Oncology, 2010 - cir.nii.ac.jp
Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.
RC Smallridge, JA Copland - Clinical Oncology (Royal College of …, 2010 - europepmc.org
Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally.
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …